Investor Relations

Corporate Profile

Fractyl Health is a clinical-stage metabolic therapeutics company focused on pioneering new approaches to treat obesity and T2D. Our Revita® and Rejuva® platform candidates are designed to target root causes of metabolic diseases and break the pattern of metabolic disease treatment from chronic management to potentially prevent and reverse metabolic disease. Fractyl Health is based in Burlington, Massachusetts.

Corporate Presentation

Minimum 15 minutes delayed. Source: LSEG

News Releases

Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 3, 2025

Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025

Feb 24, 2025

Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025

Jan 31, 2025

Events

Fractyl Health 4Q 2024 Financial Results and Business Update Conference Call

Mar 3, 2025 | 4:30 PM EST

Piper Sandler 36th Annual Healthcare Conference

Dec 4, 2024 | 1:30 PM EST

SEC Filings

Report of unscheduled material events or corporate event

Mar 03, 2025 | Form Type: 8-K

Mar 03, 2025

Annual report which provides a comprehensive overview of the company for the past year

Mar 03, 2025 | Form Type: 10-K

Mar 03, 2025

Investor Relations Contacts

Brian Luque, Head of Investor Relations and Corporate Development

Email: [email protected]
Phone: 951.206.1200

Lisa Davidson, Chief Financial Officer

Email: [email protected]
Phone: 781.902.8800